Pfizer: Fresh hope as manufacturer says COVID-19 vaccine is 90% effective, to be available soon

- A COVID-19 vaccine which is in its phase 3 trial has been found to be 90% effective, according to the manufacturer - The vaccine which is being developed by Pfizer/BioNTech has also shown no serious side-effects

- A COVID-19 vaccine which is in its phase 3 trial has been found to be 90% effective, according to the manufacturer

- The vaccine which is being developed by Pfizer/BioNTech has also shown no serious side-effects

- If granted speedy licensing by the regulators, the vaccine may be available by the end of the year 2020

PAY ATTENTION: Help us change more lives, join TUKO.co.ke’s Patreon programme

The coronavirus pandemic may soon become a thing of the past as a vaccine being developed by Pfizer/BioNTech against the novel virus is in sight, according to a report by The Guardian UK.

The news media reported that the manufacturers' announcement of the first interim results in large-scale trials shows the vaccine, which is in its phase 3 trial, is 90% effective.

An analysis of the vaccine shows a much better performance than most experts had hoped for. The company also said findings have shown that the vaccine does not have serious side-effects.

Read also

Alfred Mutua suspends nationwide political tours due to surge of COVID-19 infections

Relevant regulators have said they would approve a vaccine that is just 50% effective.

The phase 3 trials have involved more than 43,000 people.

According to the company, the gathering of the required safety data will take until the third week of November after which the dossier will be submitted to the regulators for approval.

If the vaccine is considered for speedy licensing, the first doses may be available and given to healthcare workers by the end of the year 2020.

A little over a week ago, TUKO.co.ke reported Kenya started the clinical trial to examine the effectiveness and safety of ChAdOx1 nCoV-19, which is a COVID-19 vaccine candidate.

The Kenya Medical Research Institute (KEMRI) said the trial team had vaccinated its first volunteer after receiving the necessary regulatory and ethical approvals.

This was a result of the longstanding collaboration between KEMRI, University of Oxford and the Wellcome Trust in the UK.

Do you have a groundbreaking story you would like us to publish? Please reach us through news@tuko.co.ke or WhatsApp: 0732482690. Contact Tuko.co.ke instantly.

My dad died without forgiving me - Joseph Wambua | Tuko TV

Subscribe to watch new videos

Source: TUKO.co.ke

ncG1vNJzZmivp6x7tcHKqGWcp16gsnB%2Fl3JwaXFdmLyzu82araKqpah6rq3Nrp2am6Sqv6a%2BjK%2BYnJuZo7JuhY9mnJ%2BelZjBqsLEZpivmZmhrqO4xGaqqKeeY7W1ucs%3D

 Share!